NeOnc Technologies Holdings, a Phase 2 biotech developing intranasal and oral therapies for brain cancer, withdrew its plans for an initial public offering on Wednesday. It had filed to raise $75 million by offering 6 million shares at a price range of $11.25 to $13.75.
The Westlake Village, CA-based company was founded in 2008 and had planned to list on the Nasdaq under the symbol NTHI. Loop Capital Markets was set to be the sole bookrunner on the deal.
